ACADIA PHARMACEUTICALS INC (ACAD) competitors & alternatives
Health Care · NASDAQ
ACADIA PHARMACEUTICALS INC (ACAD)'s top competitors and alternatives — its most similar public companies — include Lilly (Eli) (LLY), BIOHAVEN LTD (BHVN), TAYSHA GENE THERAPIES INC (TSHA), ANAVEX LIFE SCIENCES CORP (AVXL), SUPERNUS PHARMACEUTICALS INC (SUPN), MINERVA NEUROSCIENCES INC (NERV), VANDA PHARMACEUTICALS INC (VNDA), ZEVRA THERAPEUTICS INC (ZVRA), MIRUM PHARMACEUTICALS INC (MIRM), X4 PHARMACEUTICALS INC (XFOR), DENALI THERAPEUTICS INC (DNLI) and ETON PHARMACEUTCIALS INC (ETON). These are ACADIA PHARMACEUTICALS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top ACAD competitors & alternatives
-
Lilly (Eli)LLYHealth Care
A global pharmaceutical powerhouse developing innovative medicines across cardiometabolic, oncology, and immunology with blockbuster GLP-1 and weight-loss…
$1,163.01 (as of 2026-07-22) · market cap $1.09T
-
BIOHAVEN LTDBHVNHealth Care
Biohaven is a clinical-stage biopharmaceutical company developing innovative therapies for immunology, neurological disorders, and metabolic diseases using…
$14.75 (as of 2026-07-22) · market cap $2.3B
-
TAYSHA GENE THERAPIES INCTSHAHealth Care
Taysha Gene Therapies is a clinical-stage biotech company pioneering AAV-based gene therapies to treat severe, rare monogenic diseases of the central nervous…
$5.66 (as of 2026-07-22) · market cap $1.8B
-
ANAVEX LIFE SCIENCES CORPAVXLHealth Care
Anavex is a clinical-stage biotech developing sigma-1 receptor agonists for neurodegenerative and rare CNS disorders, with lead program ANAVEX 2-73 in multiple…
$2.55 (as of 2026-07-22) · market cap $234M
-
SUPERNUS PHARMACEUTICALS INCSUPNHealth Care
Supernus is a biopharmaceutical company commercializing approved CNS treatments across ADHD, Parkinson's disease, postpartum depression, epilepsy, and migraine…
$46.94 (as of 2026-07-22) · market cap $2.8B
-
MINERVA NEUROSCIENCES INCNERVHealth Care
Minerva Neurosciences is a clinical-stage biopharmaceutical company developing novel treatments for central nervous system disorders, primarily focusing on…
$4.43 (as of 2026-07-22) · market cap $209M
-
VANDA PHARMACEUTICALS INCVNDAHealth Care
Niche biopharmaceutical company commercializing approved therapies for psychiatry, sleep disorders, and multiple sclerosis while pursuing pipeline expansion in…
$5.35 (as of 2026-07-22) · market cap $329M
-
ZEVRA THERAPEUTICS INCZVRAHealth Care
Zevra brings life-changing therapies to ultra-rare neurodegenerative and metabolic diseases, with FDA-approved MIPLYFFA for Niemann-Pick disease type C now…
$12.14 (as of 2026-07-22) · market cap $762M
-
MIRUM PHARMACEUTICALS INCMIRMHealth Care
Mirum is a rare disease biopharmaceutical company commercializing approved bile acid and hepatic therapies while advancing late-stage candidates in cholestatic…
$114.48 (as of 2026-07-22) · market cap $7.0B
-
X4 PHARMACEUTICALS INCXFORHealth Care
A commercial-stage biopharmaceutical company focused on developing and marketing targeted therapies for rare immune system disorders, headlined by its…
$3.69 (as of 2026-07-22) · market cap $361M
-
DENALI THERAPEUTICS INCDNLIHealth Care
Denali Therapeutics is a clinical-stage biopharmaceutical company developing a proprietary platform to transport large-molecule medicines across the…
$23.64 (as of 2026-07-22) · market cap $3.7B
-
ETON PHARMACEUTCIALS INCETONHealth Care
Eton Pharmaceuticals develops and commercializes rare disease treatments, with a portfolio of ten marketed products and four late-stage candidates targeting…
$43.58 (as of 2026-07-22) · market cap $1.2B
Not quite? Describe exactly what you want →
Peers are ACADIA PHARMACEUTICALS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: ACADIA PHARMACEUTICALS INC (ACAD).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.